Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study

Background/aim: Studies regarding effectiveness of anakinra and tocilizumab treatments in coronavirus disease 2019 (COVID-19) have contradictory results. Furthermore, there is scarce comparative data regarding superiority of any agent. To further elucidate any superiority between these two agents, we retrospectively investigated and compared outcomes in hospitalized COVID-19 patients of our inpatient cohort who received anakinra or tocilizumab. Materials and methods: This study was designed as a single-center, retrospective, cross-sectional cohort study. Hospitalized patients with confirmed diagnosis of COVID-19 who had Brescia-COVID respiratory severity scale score ≥3 and hyperinflammation (defined as elevation of C reactive protein ≥50 g/L or ferritin ≥700 ng/mL) and received anakinra or tocilizumab in addition to standard care were enrolled in the study. Length of hospital stay after initiation of antiinflammatory treatment, need for mechanical ventilation, need for intensive care unit admission, mortality were set as primary outcomes and compared between tocilizumab and anakinra recipients after propensity score matching. Results: One hundred and six patients were placed in each group after propensity score matching. In the anakinra group, relative risk reduction for intensive care unit admission was 50% when compared to the tocilizumab group and the number needed to treat to avert an intensive care unit admission was 3 (95% CI, 2–5). In terms of mortality, a 52% relative risk reduction was observed with anakinra treatment and the number needed to treat to avert an intensive care unit admission was 8 (95% CI, 4–50). Significantly more patients were observed to receive glucocorticoids in the anakinra group. Conclusion: Anakinra administration in severe COVID-19 patients was significantly associated with better survival and greater clinical improvement compared to the tocilizumab administration in our study. Increased rate of glucocorticoid use in the anakinra group might have contributed to better outcomes.

Anahtar Kelime: COVID-19 cytokine storm hyperinflammation anakinra tocilizumab

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine 2020; 382 (18): 1708-1720. https:// doi.org/10.1056/NEJMoa2002032
2. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. The Journal of Heart and Lung Transplantation 2020; 39 (5): 405-407. https://doi.org/10.1016/j.healun.2020.03.012
3. Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 395 (10223): 497-506. https://doi. org/10.1016/S0140-6736(20)30183-5
4. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine & Growth Factor Reviews 2020; 53: 25-32. https://doi. org/10.1016/j.cytogfr.2020.05.003
5. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Frontiers in Immunology 2020; 11: 1446. https://doi.org/10.3389/ fimmu.2020.01446
6. Aomar-Millán IF, Salvatierra J, Hernández-Quero J. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID 19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply. Internal and Emergency Medicine 2021; 16 (4): 1–2. https:// doi.org/10.1007/s11739-021-02690-3
7. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host & Microbe 2020; 27 (6): 992-1000.e3. https://doi.org/10.1016/j. chom.2020.04.009
8. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomised clinical trial. JAMA Internal Medicine 2021; 181 (1): 24–31. https://doi.org/10.1001/jamainternmed.2020.6615
9. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomised clinical trial. JAMA Internal Medicine 2021; 181 (1): 32–40. https://doi.org/10.1001/jamainternmed.2020.6820
10. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L et al. Efficacy of tocilizumab in patients hospitalised with COVID-19. New England Journal of Medicine 2020; 383 (24): 2333–2344. https://doi.org/10.1056/NEJMoa2028836
11. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD et al. Tocilizumab in hospitalised patients with COVID-19 pneumonia. New England Journal of Medicine 2021; 384 (16): 1503- 1516. https://doi.org/10.1056/NEJMoa2028700
12. Salama C, Han J, Yau L, Reiss WG, Kramer B et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine 2021; 384 (1): 20–30. https://doi. org/10.1056/NEJMoa2030340
13. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. Journal of Medical Virology 2020; 92 (7): 814-818. https://doi.org/10.1002/ jmv.25801
14. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews 2020; 19 (7): 102568. https://doi. org/10.1016/j.autrev.2020.102568
15. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology 2020; 2 (8): e474-e484. https://doi.org/10.1016/S2665-9913(20)30173-9
16. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology 2020; 2 (6): e325– 31. https://doi.org/10.1016/ S2665-9913(20)30127-2
17. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G et al. Anakinra for severe forms of COVID-19: a cohort study. The Lancet Rheumatology 2020; 2 (7): e393–400. https://doi. org/10.1016/S2665-9913(20)30164-8
18. Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. International Journal of Infectious Diseseases 2021; 103: 288–96. https://doi. org/10.1016/j.ijid.2020.11.149
19. CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. The Lancet Respiratory Medicine 2021; 9 (3): 295-304. https://doi.org/10.1016/S2213- 2600(20)30556-7
20. Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. The Lancet Rheumatology 2021; 3 (4): e253-e261. https://doi.org/10.1016/S2665- 9913(21)00012-6
21. Lombardy Section Italian Society Infectious And Tropical Diseases -. Vademecum for the 19 treatment of people with COVID-19. Edition 2.0, 13 March 2020. Le Infezioni in Medicina 2020; 28 (2): 143-152.
22. Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine 2020; 18 (1): 405. https://doi. org/10.1186/s12967-020-02573-9
23. Dai H, Zhang X, Xia J, Zhang T, Shang Y et al. High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China. International Journal of Infectious Diseases 2020; 95: 106-112. https://doi. org/10.1016/j.ijid.2020.04.003
24. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 2020; 395 (10229): 1033. https://doi.org/10.1016/S0140-6736(20)30628-0
25. Shrivastava G, León-Juárez M, García-Cordero J, Meza-Sánchez DE, Cedillo-Barrón L. Inflammasomes and its importance in viral infections. Immunologic Research 2016; 64 (5-6): 1101- 1117. https://doi.org/10.1007/s12026-016-8873-z
26. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368 (6490): 473-474. https://doi. org/10.1126/science.abb8925
27. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmunity Reviews 2020; 19 (7): 102567. https://doi.org/10.1016/j. autrev.2020.102567
28. Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clinica Chimica Acta 2020; 509: 180- 194. https://doi.org/10.1016/j.cca.2020.06.009
29. Yang Y, Shen C, Li J, Yuan J, Wei J et al. Plasma IP-10 and MCP- 3 levels are highly associated with disease severity and predict the progression of COVID-19. The Journal of Allergy and Clinical Immunology 2021; 146 (1): 119-127.e4. https://doi. org/10.1016/j.jaci.2020.04.027.
30. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133 (2): 235-249. https://doi.org/10.1016/j.cell.2008.02.043
31. Biran N, Ip A, Ahn J, Go RC, Wang S et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology 2020; 2 (10): e603-e612. https://doi.org/10.1016/S2665-9913(20)30277-0
32. Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. International Journal of Antimicrobial Agents 2020; 56 (3): 106103. https://doi.org/10.1016/j. ijantimicag.2020.106103
33. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA et al. Cytokine release syndrome. Journal for ImmunoTherapy of Cancer 2018; 6 (1): 56. https://doi. org/10.1186/s40425-018-0343-9
34. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID 19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine 2020; 46 (5): 846-848. https://doi.org/10.1007/s00134-020-05991-x
35. Erden A, Ozdemir B, Karakas O, Mutlu NM, Izdes S et al. Evaluation of 17 patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA, and Brescia-COVID respiratory severity scale (BCRSS) scoring systems. Journal of Medical Virology 2021; 93 (3): 1532-1537. https://doi.org/10.1002/jmv.26473
36. Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 2015; 54 (12): 2134-2144. https://doi. org/10.1093/rheumatology/kev269
37. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nature Reviews Rheumatology 2016; 12 (5): 259-268. https://doi.org/10.1038/ nrrheum.2015.179
38. Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/ macrophage activating syndrome in critically ill children*. Pediatric Critical Care Medicine 2014; 15 (5): 401-408. https:// doi.org/10.1097/PCC.0000000000000078
39. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M et al. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine 2021; 384 (8): 693-704. https://doi.org/10.1056/NEJMoa2021436

APA	küçükşahin o, erden a, karakaş ö, Güven S, Armagan B, Şahiner E, İNAN O, Kurtipek A, GEMCİOĞLU E, KARAAHMETOGLU S, turan s, Izdes S, Erdem D, Altunsoy A, Ayhan M, Akıncı E, Bodur H, GÜNER R, Omma A, ateş i (2022). Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. , 1486 - 1494. 10.55730/1300-0144.5487
Chicago	küçükşahin orhan,erden abdulsamet,karakaş özlem,Güven Serdar Can,Armagan Berkan,Şahiner Enes seyda,İNAN OSMAN,Kurtipek Ali Can,GEMCİOĞLU EMİN,KARAAHMETOGLU SELMA,turan sema,Izdes Seval,Erdem Deniz,Altunsoy Adalet,Ayhan Müge,Akıncı Esragül,Bodur Hurrem,GÜNER RAHMET,Omma Ahmet,ateş ihsan Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. (2022): 1486 - 1494. 10.55730/1300-0144.5487
MLA	küçükşahin orhan,erden abdulsamet,karakaş özlem,Güven Serdar Can,Armagan Berkan,Şahiner Enes seyda,İNAN OSMAN,Kurtipek Ali Can,GEMCİOĞLU EMİN,KARAAHMETOGLU SELMA,turan sema,Izdes Seval,Erdem Deniz,Altunsoy Adalet,Ayhan Müge,Akıncı Esragül,Bodur Hurrem,GÜNER RAHMET,Omma Ahmet,ateş ihsan Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. , 2022, ss.1486 - 1494. 10.55730/1300-0144.5487
AMA	küçükşahin o,erden a,karakaş ö,Güven S,Armagan B,Şahiner E,İNAN O,Kurtipek A,GEMCİOĞLU E,KARAAHMETOGLU S,turan s,Izdes S,Erdem D,Altunsoy A,Ayhan M,Akıncı E,Bodur H,GÜNER R,Omma A,ateş i Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. . 2022; 1486 - 1494. 10.55730/1300-0144.5487
Vancouver	küçükşahin o,erden a,karakaş ö,Güven S,Armagan B,Şahiner E,İNAN O,Kurtipek A,GEMCİOĞLU E,KARAAHMETOGLU S,turan s,Izdes S,Erdem D,Altunsoy A,Ayhan M,Akıncı E,Bodur H,GÜNER R,Omma A,ateş i Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. . 2022; 1486 - 1494. 10.55730/1300-0144.5487
IEEE	küçükşahin o,erden a,karakaş ö,Güven S,Armagan B,Şahiner E,İNAN O,Kurtipek A,GEMCİOĞLU E,KARAAHMETOGLU S,turan s,Izdes S,Erdem D,Altunsoy A,Ayhan M,Akıncı E,Bodur H,GÜNER R,Omma A,ateş i "Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study." , ss.1486 - 1494, 2022. 10.55730/1300-0144.5487
ISNAD	küçükşahin, orhan vd. "Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study". (2022), 1486-1494. https://doi.org/10.55730/1300-0144.5487

APA	küçükşahin o, erden a, karakaş ö, Güven S, Armagan B, Şahiner E, İNAN O, Kurtipek A, GEMCİOĞLU E, KARAAHMETOGLU S, turan s, Izdes S, Erdem D, Altunsoy A, Ayhan M, Akıncı E, Bodur H, GÜNER R, Omma A, ateş i (2022). Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. Turkish Journal of Medical Sciences, 52(5), 1486 - 1494. 10.55730/1300-0144.5487
Chicago	küçükşahin orhan,erden abdulsamet,karakaş özlem,Güven Serdar Can,Armagan Berkan,Şahiner Enes seyda,İNAN OSMAN,Kurtipek Ali Can,GEMCİOĞLU EMİN,KARAAHMETOGLU SELMA,turan sema,Izdes Seval,Erdem Deniz,Altunsoy Adalet,Ayhan Müge,Akıncı Esragül,Bodur Hurrem,GÜNER RAHMET,Omma Ahmet,ateş ihsan Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. Turkish Journal of Medical Sciences 52, no.5 (2022): 1486 - 1494. 10.55730/1300-0144.5487
MLA	küçükşahin orhan,erden abdulsamet,karakaş özlem,Güven Serdar Can,Armagan Berkan,Şahiner Enes seyda,İNAN OSMAN,Kurtipek Ali Can,GEMCİOĞLU EMİN,KARAAHMETOGLU SELMA,turan sema,Izdes Seval,Erdem Deniz,Altunsoy Adalet,Ayhan Müge,Akıncı Esragül,Bodur Hurrem,GÜNER RAHMET,Omma Ahmet,ateş ihsan Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. Turkish Journal of Medical Sciences, vol.52, no.5, 2022, ss.1486 - 1494. 10.55730/1300-0144.5487
AMA	küçükşahin o,erden a,karakaş ö,Güven S,Armagan B,Şahiner E,İNAN O,Kurtipek A,GEMCİOĞLU E,KARAAHMETOGLU S,turan s,Izdes S,Erdem D,Altunsoy A,Ayhan M,Akıncı E,Bodur H,GÜNER R,Omma A,ateş i Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. Turkish Journal of Medical Sciences. 2022; 52(5): 1486 - 1494. 10.55730/1300-0144.5487
Vancouver	küçükşahin o,erden a,karakaş ö,Güven S,Armagan B,Şahiner E,İNAN O,Kurtipek A,GEMCİOĞLU E,KARAAHMETOGLU S,turan s,Izdes S,Erdem D,Altunsoy A,Ayhan M,Akıncı E,Bodur H,GÜNER R,Omma A,ateş i Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. Turkish Journal of Medical Sciences. 2022; 52(5): 1486 - 1494. 10.55730/1300-0144.5487
IEEE	küçükşahin o,erden a,karakaş ö,Güven S,Armagan B,Şahiner E,İNAN O,Kurtipek A,GEMCİOĞLU E,KARAAHMETOGLU S,turan s,Izdes S,Erdem D,Altunsoy A,Ayhan M,Akıncı E,Bodur H,GÜNER R,Omma A,ateş i "Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study." Turkish Journal of Medical Sciences, 52, ss.1486 - 1494, 2022. 10.55730/1300-0144.5487
ISNAD	küçükşahin, orhan vd. "Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study". Turkish Journal of Medical Sciences 52/5 (2022), 1486-1494. https://doi.org/10.55730/1300-0144.5487